文献速递药物不良反应与药物警戒

A型肉毒毒素真实世界应用不良事件:FAERS数据库分析

A study on adverse events of botulinum toxin type A in real-world applications: A FAERS database analysis.
PubMed 文献 · Br J Clin Pharmacol · 2025-07-02

本研究基于FAERS数据库,采用ROR、PRR、BCPNN和MGPS四种方法评估A型肉毒毒素(BoNT-A)相关不良事件的不比例性。在17 307 196份报告中,69 644份以BoNT-A为主要可疑药物,涉及27个系统器官分类,筛选出290个PT层面显著不比例信号,包括说明书未提及的皮肤皱纹、听觉过敏、吉兰-巴雷综合征、纵隔炎和感染性动脉瘤等非预期不良事件。结论提示BoNT-A总体安全谱较广,多数不良事件为轻中度,但临床需警惕严重不良事件。

要点

  • BoNT-A相关不良事件涉及27个系统器官分类,筛选出290个PT层面显著信号。
  • 发现说明书未提及的非预期不良事件,如吉兰-巴雷综合征、纵隔炎和感染性动脉瘤。
  • 多数不良事件为轻中度,但临床仍需监测严重不良事件。

核心结论

  • BoNT-A真实世界应用安全性谱较广,多数不良事件为轻中度,但需警惕严重不良事件并在临床中监测。

研究设计与样本

  • 基于FAERS数据库的药物警戒研究,采用ROR、PRR、BCPNN和MGPS四种方法评估BoNT-A相关不良事件的不比例性。
  • FAERS数据库共17 307 196份病例报告,其中69 644份以BoNT-A为主要可疑药物。

主要发现

  • BoNT-A相关不良事件涉及27个系统器官分类。
  • 四种算法共保留290个PT层面显著不比例信号。
  • 发现说明书未提及的非预期不良事件,包括皮肤皱纹、听觉过敏、吉兰-巴雷综合征、纵隔炎和感染性动脉瘤。

临床怎么用

  • 临床使用BoNT-A时应关注说明书未提及的非预期不良事件信号,如吉兰-巴雷综合征、纵隔炎和感染性动脉瘤。
  • 对BoNT-A相关不良事件保持警惕,尤其需监测严重不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Botulinum toxin type A (BoNT-A) is widely used for its efficacy in treating a variety of neuromuscular disorders. However, data on its safety and adverse events (AEs) in real-world settings remain limited. The Food and Drug Administration Adverse Event Reporting System (FAERS) database provides an invaluable resource for evaluating the safety of BoNT-A. METHODS: We used four methods to evaluate the disproportionality of AEs associated with BoNT-A: the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS). RESULTS: Among the 17 307 196 case reports in the FAERS database, there were 69 644 reports where BoNT-A was listed as the "primary suspect" for AEs. BoNT-A-related AEs affected 27 system organ classes (SOCs). Based on the four algorithms, 290 significant disproportionalities at the Preferred Term (PT) level were retained. Unexpected AEs, such as skin wrinkles, hyperacusis, Guillain-Barré syndrome, mediastinitis and infective aneurysm, were identified, which are not mentioned in the product insert. CONCLUSION: This study provides an overview of AEs in the real-world use of BoNT-A, revealing its broad safety profile. Although the majority of AEs were mild to moderate, there is a need to remain vigilant for serious AEs and to monitor them in clinical practice.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. He W, Guo J, Xu Y, et al. A study on adverse events of botulinum toxin type A in real-world applications: A FAERS database analysis. Br J Clin Pharmacol. 2025. PMID: 40603062. doi:10.1002/bcp.70141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。